Redeye’s first take on the Q4 report this morning. Again, there were considerable changes in sales i...
Redeye is encouraged to see organic growth in the quarter after a relatively weak performance during...
Redeye continues to see a compelling long-term investment case.
Redeye updates its estimates and valuation following Vitec releasing its Q4 2024 report.
Q4'24 results due 11 February '25e-'26e adj. EBIT revised by 0.
Hyresintäkterna steg med 38% till 12,4 meur och förvaltningsresultat ökade med 37% till 6,2 meur på ...
Finnair reports Q4 results on Feb 13. Q4 traffic data was mostly encouraging even if European routes...
F&MT initiates cost-cutting program Gradual recovery expected Q4 due on 10 February Q4e: Organic sa...
On February 4thth, Eevia Health Plc (publ) (“Eevia”) announced that the Company has agreed to sell I...
Redeye’s first comments follow this morning’s Q4 report from Tagmaster.
Redeye comments on the Q4 report released earlier this morning.
Redeye returns with a more in-depth take on OssDsign’s Q4 report.
Redeye maintains its fair value range for Sleep Cycle following the Q4 2024 report, which met our sa...
Sales and gross margin above expectations in Q4 EBIT revised up by 2.
Kingspan bids SEK 182.5/shareNWG's board recommends accepting the bidHighly likely the bid will go t...
